NEW YORK (360Dx) – Danaher's Leica Biosystems said today that the US Food and Drug Administration has cleared its Aperio AT2 DX System for clinical diagnosis in the US.

The Aperio AT2 DX System is a high-throughput automated scanning and viewing platform. Vista, California-based Leica said that it will be launched with clinical image management software for an integrated digital pathology workflow solution.